Image source: © 2025 Krish Capital Pty.Ltd

Highlights

  • JPMorgan Chase lifts Roivant Sciences’ price target to USD 20.00 from USD 16.00.
  • Consensus analyst rating stands at “Buy” with average target price of USD 19.94.
  • Insider transactions include recent share sales by Vivek Ramaswamy and CEO share purchases.

JPMorgan Chase & Co. increased its target price for Roivant Sciences Ltd. (NASDAQ:ROIV) from USD 16.00 to USD 20.00 in a research note issued on Thursday, according to Benzinga. The brokerage maintained an “overweight” rating, citing potential upside of 32.98% based on the stock’s prior closing price.

Other analysts have also revised their outlooks. Bank of America raised its target from USD 12.00 to USD 16.50 while assigning a “neutral” rating. Goldman Sachs upgraded Roivant to a “strong-buy” with a target of USD 19.00 in July. Citigroup initiated coverage in September with a “buy” rating and a USD 16.00 target. Leerink Partners increased its target from USD 18.00 to USD 22.00 alongside an “outperform” rating, and HC Wainwright moved its estimate from USD 18.00 to USD 20.00 while maintaining a “buy” recommendation.

In total, one analyst issued a “strong-buy,” seven assigned a “buy,” and one issued a “hold.” Data from MarketBeat indicates a consensus “Buy” rating and an average target price of USD 19.94.

Roivant Sciences is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies in inflammation and immunology. The firm operates through its “Vants” structure, which incubates and develops medicines, discovery-stage biotechnology, and health technology businesses.

Insider trading activity was recently disclosed. Major shareholder Vivek Ramaswamy sold 1,195,000 shares on September 3rd at an average price of USD 12.50, generating USD 14.94 million. Following the sale, his ownership decreased by 3.21% to 36,089,108 shares, valued at approximately USD 451.11 million.

In contrast, CEO Matthew Gline acquired 3,315 shares on September 18th at an average cost of USD 15.07 per share, totaling USD 49,957.05. His holdings increased marginally by 0.02% to 17,287,081 shares, valued at about USD 260.52 million.

Overall, insiders sold 1,975,749 shares valued at USD 24.78 million during the last quarter, while insiders collectively hold 10.80% of Roivant’s outstanding shares.